



Cipla receives approval for generic version of Shire's Firazyr®

14 July 2020 | News

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr®

The Cipla logo, consisting of the word "Cipla" in a bold, blue, sans-serif font.

Cipla Limited has announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).

Cipla's Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's Firazyr®. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

According to IQVIA (IMS Health), Firazyr® and its generic equivalents had US sales of approximately \$270M for the 12-month period ending May 2020.